STOCK TITAN

EXELIXIS (EXEL) SEC Filings, Feb 12-18, 2026

EXEL NASDAQ

Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.

Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.

Rhea-AI Summary

Brenda Joy Hefti, an officer of Exelixis, Inc., reported a proposed sale of 18,669 common shares with an aggregate market value of $821,663.76; the approximate sale date is February 18, 2026. The notice lists November 19, 2025, as the date of plan adoption or giving of instruction under Rule 10b5-1. Hefti acquired 9,310 performance shares from the issuer on January 16, 2025, and 9,359 performance shares from the issuer on February 15, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.70%
Tags
other
-
Form 144
Rhea-AI Summary

Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the planned sale of 99,574 Common shares with an aggregate value of $4,382,506.87 on 02/18/2026. The notice lists prior issuances and exercises of Common stock on several dates, including 03/29/2021, 04/01/2019, 05/21/2021, 05/23/2020, and 04/04/2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.70%
Tags
other
-
Rhea-AI Summary

A shareholder of Exelixis filed a notice to sell 42,422 shares of common stock under Rule 144. The shares are expected to be sold on or about 02/17/2026 through NASDAQ, with Morgan Stanley Smith Barney LLC listed as the broker.

These shares were acquired on 02/17/2026 through a stock option exercise from the issuer, paid for in cash, and have an indicated aggregate market value of $1,880,439.99. The filing notes that total shares outstanding are 259,708,689 for context.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
other
Rhea-AI Summary

A company insider has filed a Form 144 indicating an intent to sell 30,617 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,337,035.20. The shares, classified as performance shares, were acquired from the issuer on 02/15/2026, with the same date listed for payment. The approximate sale date is 02/17/2026 on the NASDAQ market. Over the prior three months, Christopher J. Senner sold 34,278 common shares for $1,473,964.28. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
other
-
Rhea-AI Summary

Exelixis insider Patrick Joseph Haley has filed a notice to sell up to 67,814 shares of the company’s common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an indicated aggregate market value of $2,951,082.94 based on the figures in the notice.

The shares to be sold were acquired as performance shares from the issuer on January 15, 2026 (37,421 shares) and February 15, 2026 (30,393 shares), with payment listed as not applicable. The notice also shows that Haley previously sold common shares during November 2025 in three transactions totaling tens of thousands of shares, with individual gross proceeds of $1,194,070.94, $421,052.00, and $1,431,757.23.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
other
-
Rhea-AI Summary

Exelixis Inc. has a shareholder planning to sell restricted shares under Rule 144. The notice covers 3,856 shares of Exelixis common stock to be sold through UBS Financial Services on NASDAQ, with an approximate aggregate market value of $165,383.84. These shares were acquired as restricted stock units from the issuer on 01/05/2026, the same date listed as the payment date. The filing also reports that Exelixis had 259,708,689 shares of common stock outstanding, providing context for the size of this planned sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
other
Rhea-AI Summary

Exelixis has a planned Rule 144 sale of 34,278 common shares, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The filing lists an aggregate market value of 1,473,964.28 for these shares.

The shares were acquired as performance shares from the issuer on 01/15/2026, with the same date shown for payment and the nature of payment marked "Not Applicable." The document notes 259,708,689 shares outstanding, giving context for the size of this potential sale, and indicates an approximate sale date of 02/13/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
other
-
Rhea-AI Summary

A holder filed a notice of proposed sale under Rule 144 to sell 30,250 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC on 02/13/2026 on NASDAQ. The filing shows an aggregate market value of $1,325,407.81 for these planned sales.

The shares were acquired as restricted stock on 05/31/2025 totaling 21,162 shares with no cash payment noted, and 9,088 shares from a stock option exercise on 02/13/2026 paid in cash. Shares outstanding were 259,708,689 at the time indicated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
other
-
Rhea-AI Summary

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 13,658,388 shares of Exelixis, Inc. common stock, representing 5.09% of the class. They hold shared power to vote and dispose of these shares, with no sole voting or dispositive power.

The firms state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Exelixis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
ownership
Rhea-AI Summary

Exelixis, Inc. insider plans Rule 144 sale of common stock. A holder has filed to sell 5,000 shares of Exelixis common stock through Morgan Stanley Smith Barney LLC on or around 02/12/2026 on the NASDAQ, with an aggregate market value of $216,250 at the time of the notice.

The shares were received as a gift from an affiliate, identified as Michael Morrissey/Morrissey Family Trust, on 11/11/2025, with the donor having originally acquired them on 10/02/2019. The filing notes 259,708,689 common shares outstanding, providing a baseline for the size of this planned sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
other

FAQ

How many EXELIXIS (EXEL) SEC filings are available on StockTitan?

StockTitan tracks 102 SEC filings for EXELIXIS (EXEL), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for EXELIXIS (EXEL)?

The most recent SEC filing for EXELIXIS (EXEL) was filed on November 9, 2026.